BRCA2 Gene Mutation Testing (Germline, Sequencing)
This test checks for changes (mutations) in the BRCA2 gene, which can increase your risk of certain cancers, including breast and ovarian cancer.
["Identifying BRCA2 mutations helps guide cancer prevention and early detection strategies."]
Key facts at a glance
- LOINC
- 72518-4
- Short code
- CHEK2
- Synonyms
- CHEK2 c.470C>T+1100delC Bld/T
- Category
- chemistry
- Sample
- whole-blood
- Container
- EDTA (lavender/purple-top) tube for whole blood; sterile container for tissue specimens. Maintain specimen at 2-8°C during transport.
- Units
- N/A
- Fasting
- false
- Population
- adult
- Sex
- all
- Age range
- ≥ 0 years
- Method
- molgen
- CPT
- 81215
- SNOMED
- 76619-7
- Specimen volume
- 3-5 mL whole blood in EDTA tube OR minimum 5 mg tissue with high tumor/dna content. Pediatric minimum: 1-2 mL whole blood in EDTA.
- Stability
- Whole blood: stable at room temperature for 24 hours, refrigerated (2-8°C) for up to 7 days; do not freeze. Extracted DNA: stable at 2-8°C for 1 week, -20°C for long-term storage. Tissue: stable in sterile saline or transport medium at 2-8°C for 24-48 hours.
- Hemolysis max
- 0
- Lipemia max
- 0
- Icterus max
- 0
- TAT
- 168–720 hours
- Order
- routine
Why This Test Might Be Ordered
Your healthcare provider may recommend this test if you have a strong family history of breast, ovarian, prostate, or other related cancers, or if you’ve been diagnosed with certain types of cancer at a younger age. It may also be suggested for individuals with a personal history of certain cancers or genetic syndromes linked to BRCA2 mutations.
What to Expect Before the Test
You’ll typically provide a blood sample, which is drawn from a vein in your arm. The process is quick and usually painless. No special preparation is needed, but discuss any medications or health conditions with your provider beforehand.
What the Results Mean
Results can be categorized as negative (no BRCA2 mutations found), positive (mutations detected), or uncertain (ambiguous results). A positive result means you carry the mutation and may be at higher risk for certain cancers. Discuss results with your healthcare team to understand next steps, such as monitoring, risk-reducing options, or genetic counseling.
Next Steps After Testing
If you test positive, your provider may recommend regular cancer screenings, medications to reduce risk, or referrals to genetic counseling. If negative, ongoing monitoring may still be advised based on your family history and other risk factors.
Reference range
Negative for CHEK2 c.470C>T and 1100delC pathogenic variants. Positive indicates heterozygous or homozygous carrier status for the tested mutation.N/A
Informed consent for genetic testing is recommended prior to sample collection. Genetic counseling pre- and post-test is advisable to discuss implications, family planning, and cancer risk management.
Clinical interpretation
How abnormal results are interpreted and what conditions they suggest.
Clinical Significance
Short name
BRCA2 Mutation Test
Frequently asked questions
What does a positive BRCA2 mutation mean for my health?
Can I still have children if I have a BRCA2 mutation?
How often should I get cancer screenings if I have a BRCA2 mutation?
Sources
- 1
- 2Lab Tests OnlineSource
- 3
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy